{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:31:38Z","timestamp":1772173898019,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1038\/s41577-020-0358-6","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T11:02:43Z","timestamp":1591268563000},"page":"399-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["COVID-19 vaccines: neutralizing antibodies and the alum advantage"],"prefix":"10.1038","volume":"20","author":[{"given":"Peter J.","family":"Hotez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Corry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-7683","authenticated-orcid":false,"given":"Ulrich","family":"Strych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8429-0476","authenticated-orcid":false,"given":"Maria Elena","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"358_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6284","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science https:\/\/doi.org\/10.1126\/science.abc6284 (2020).","journal-title":"Science"},{"key":"358_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1932","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science https:\/\/doi.org\/10.1126\/science.abc1932 (2020).","journal-title":"Science"},{"key":"358_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.15.098079","author":"W-H Chen","year":"2020","unstructured":"Chen, W.-H. et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.05.15.098079 (2020).","journal-title":"bioRxiv"},{"key":"358_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.13.093195","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.05.13.093195 (2020).","journal-title":"bioRxiv"},{"key":"358_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31208-3","author":"F-C Zhu","year":"2020","unstructured":"Zhu, F.-C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(20)31208-3 (2020).","journal-title":"Lancet"},{"key":"358_CR6","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.13.092619","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.05.13.092619 (2020).","journal-title":"bioRxiv"},{"key":"358_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-0972-0","volume":"4","author":"TR Ghimire","year":"2015","unstructured":"Ghimire, T. R. The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro versus in vivo paradigm. Springerplus 4, 181 (2015).","journal-title":"Springerplus"},{"issue":"Suppl. 5","key":"358_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1513\/AnnalsATS.201403-105AW","volume":"11","author":"VO Millien","year":"2014","unstructured":"Millien, V. O. et al. Airway fibrinogenolysis and the initiation of allergic inflammation. Ann. Am. Thorac. Soc. 11 (Suppl. 5), 277\u2013283 (2014).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"358_CR9","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.abb8923","volume":"368","author":"BS Graham","year":"2020","unstructured":"Graham, B. S. et al. Rapid COVID-19 vaccine development. Science 368, 945\u2013946 (2020).","journal-title":"Science"},{"key":"358_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41577-020-0323-4","volume":"20","author":"PJ Hotez","year":"2020","unstructured":"Hotez, P. J., Corry, D. B. & Bottazzi, M. E. COVID-19 vaccine design: the Janus face of immune enhancement. Nat. Rev. Immunol. 20, 347\u2013348 (2020).","journal-title":"Nat. Rev. Immunol."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41577-020-0358-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41577-020-0358-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41577-020-0358-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:59:51Z","timestamp":1684619991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-020-0358-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1038\/s41577-020-0358-6","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,4]]},"assertion":[{"value":"4 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.J.H. and M.E.B. are investigators leading the development of coronavirus vaccines against SARS-CoV, MERS-CoV and SARS-CoV-2. D.B.C. is a scientific advisor and holds intellectual property in Atropos Therapeutics, LLC. U.S. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}